• +1-646-491-9876
    • +91-20-67278686

    Search

    Myocardial Ischemia Pipeline Review H1 2017

    Myocardial Ischemia Pipeline Review H1 2017

    • Report Code ID: RW0001799303
    • Category Pharmaceuticals
    • No. of Pages 64
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Myocardial Ischemia - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Ischemia - Pipeline Review, H1 2017, provides an overview of the Myocardial Ischemia (Cardiovascular) pipeline landscape.

    Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris) , neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis) , blood clot, coronary spasm and severe illnesses. The factors that may increase the risk of developing myocardial ischemia include tobacco, diabetes, high blood pressure, high blood cholesterol or triglyceride levels, lack of physical activity, obesity and family history.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Myocardial Ischemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Myocardial Ischemia (Cardiovascular) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Myocardial Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

    Myocardial Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Ischemia (Cardiovascular) .
    - The pipeline guide reviews pipeline therapeutics for Myocardial Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Myocardial Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Myocardial Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Ischemia (Cardiovascular)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Myocardial Ischemia (Cardiovascular) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Myocardial Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Myocardial Ischemia - Overview
    Myocardial Ischemia - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Myocardial Ischemia - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Myocardial Ischemia - Companies Involved in Therapeutics Development
    Angionetics Inc
    Bayer AG
    Cellmid Ltd
    CohBar Inc
    Lixte Biotechnology Holdings Inc
    NoNO Inc
    Omniox Inc
    Pathfinder Cell Therapy Inc
    Shire Plc
    Symic Biomedical Inc
    ViroMed Co Ltd
    Myocardial Ischemia - Drug Profiles
    AB-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    alferminogene tadenovec - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AntimiR-199a - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BAY-606583 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CMK-103 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EP-80317 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Humanin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LB-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OMX-4.80 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Pathfinder Cells - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptagon - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PMC-6 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SB-030 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Myocardial Ischemia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Myocardial Ischemia Reperfusion Injury - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize TRPM7 for Oncology, Ophthalmology, Cardiovascular and Central nervous System Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Cardiovascular Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VM-202 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Myocardial Ischemia - Dormant Projects
    Myocardial Ischemia - Discontinued Products
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Myocardial Ischemia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Myocardial Ischemia - Pipeline by Angionetics Inc, H1 2017
    Myocardial Ischemia - Pipeline by Bayer AG, H1 2017
    Myocardial Ischemia - Pipeline by Cellmid Ltd, H1 2017
    Myocardial Ischemia - Pipeline by CohBar Inc, H1 2017
    Myocardial Ischemia - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
    Myocardial Ischemia - Pipeline by NoNO Inc, H1 2017
    Myocardial Ischemia - Pipeline by Omniox Inc, H1 2017
    Myocardial Ischemia - Pipeline by Pathfinder Cell Therapy Inc, H1 2017
    Myocardial Ischemia - Pipeline by Shire Plc, H1 2017
    Myocardial Ischemia - Pipeline by Symic Biomedical Inc, H1 2017
    Myocardial Ischemia - Pipeline by ViroMed Co Ltd, H1 2017
    Myocardial Ischemia - Dormant Projects, H1 2017
    Myocardial Ischemia - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Myocardial Ischemia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Angionetics Inc
    Bayer AG
    Cellmid Ltd
    CohBar Inc
    Lixte Biotechnology Holdings Inc
    NoNO Inc
    Omniox Inc
    Pathfinder Cell Therapy Inc
    Shire Plc
    Symic Biomedical Inc
    ViroMed Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//myocardial-ischemia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//myocardial-ischemia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//myocardial-ischemia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments